Nature Cardiovascular Research, published by SpringerNature in Germany, stands as a premier journal dedicated to advancing the field of cardiovascular sciences. With an impressive 2023 categorization in the Q1 quartile across multiple disciplines—including Biochemistry, Genetics and Molecular Biology, Cardiology, and Medicine—this journal uniquely positions itself as a leading resource for pioneering research and innovative findings. Although currently not open access, it provides a rich repository of peer-reviewed articles that contribute directly to the evolving landscape of cardiovascular medicine. The journal aims to bridge the knowledge gap between basic science and clinical application, catering to researchers, healthcare professionals, and students alike who are immersed in the complexities of cardiovascular health. With robust Scopus rankings in key categories, Nature Cardiovascular Research is poised to shape future directions in the field, helping to foster a deeper understanding of cardiovascular diseases and their underlying mechanisms. Explore the latest research and be part of the conversation in one of the most impactful scientific domains.

JACC-Basic to Translational Science, published by Elsevier Science Inc, is a distinguished open access journal that has been advancing the field of cardiology and cardiovascular medicine since its inception in 2016. With an ISSN of 2452-302X and an impressive Q1 ranking in Cardiology and Cardiovascular Medicine as per the 2023 category quartiles, the journal is recognized for its commitment to publishing high-quality research that bridges the gap between basic science and clinical application. Operating from its base in the United States, JACC-Basic to Translational Science is at the forefront of enriching the academic community and healthcare professionals with cutting-edge studies and insights. The journal's robust reach is highlighted by its rank of #14 out of 387 in Scopus for its pertinent subject area, placing it in the 96th percentile. It aims to provide an open access platform that fosters collaboration and the exchange of ideas to ensure the continuous advancement of cardiovascular research. Readers can easily access the latest findings and contribute to the ever-evolving landscape of cardiology through this esteemed publication.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, published by Elsevier Science Ltd, is a premier scholarly journal dedicated to advancing the field of cardiology and cardiovascular medicine as well as molecular biology. With an impressive Q1 ranking in both categories as of 2023, the journal boasts a significant influence in the scientific community, evidenced by its Scopus rankings—33rd out of 387 in Cardiology and 65th out of 410 in Molecular Biology. Established in 1970 and continuing to publish groundbreaking research through 2024, the journal’s mission is to disseminate innovative findings that enhance our understanding of cardiovascular health at the molecular and cellular levels. Although it is not an open-access publication, it attracts top-tier research contributions, making it essential reading for researchers, healthcare professionals, and students aiming to stay ahead in the dynamic domains of cardiovascular and molecular biology research.

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.

CLINICAL SCIENCE, published by PORTLAND PRESS LTD, is a prestigious journal with an established history that dates back to 1946. Renowned for its rigorous peer-reviewed articles, the journal is dedicated to advancing knowledge in the field of medicine, particularly in the nuances of clinical science and translational research. With an impressive Q1 ranking in the **Medicine (miscellaneous)** category and a Scopus rank of #32 out of 636 in general medicine, it is firmly positioned in the top 5% percentile of its field, making it an essential resource for researchers, practitioners, and students aiming to stay at the forefront of the discipline. Although the journal operates on a traditional subscription model, its influence and accessibility ensure that critical findings and innovative methodologies reach a wide audience, fostering collaboration and progress within the global medical community. The journal seeks to publish groundbreaking studies, critical reviews, and insights that can translate into improved clinical practices, thus reinforcing its mission to enhance patient care and medical knowledge.

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

Journal of Cardiovascular Development and Disease, an esteemed publication by MDPI, has been a dedicated platform for disseminating cutting-edge research since its inception in 2014. Based in Switzerland, this Open Access journal not only provides unrestricted access to its content but also fosters global collaboration among scholars focusing on cardiovascular health and disease development. With an impressive focus classified as Q1 in Pharmacology, Toxicology and Pharmaceutics for 2023, it attracts a diverse range of interdisciplinary research, supporting advancements in pharmacological applications relevant to cardiac conditions. The journal's ongoing convergence through 2024 highlights its commitment to the evolving landscape of cardiovascular research, making it a vital resource for researchers, professionals, and students alike who are keen to contribute to and learn from significant developments in this critical field.